7510-46-5

Basic information

• Product Name: (2-METHOXY-4-PROPENYL-PHENOXY)-ACETIC ACID
• Synonyms: {2-methoxy-4-[(1E)-prop-1-en-1-yl]phenoxy}acetic acid;2-(2-methoxy-4-prop-1-enylphenoxy)acetic acid;2-(2-methoxy-4-prop-1-enyl-phenoxy)acetic acid;2-(2-methoxy-4-prop-1-enyl-phenoxy)ethanoic acid;2-[2-methoxy-4-[(E)-prop-1-enyl]phenoxy]acetic acid;2-[2-methoxy-4-[(E)-prop-1-enyl]phenoxy]ethanoic acid;MLS000773373;NSC405685
• CAS NO: 7510-46-5
• Molecular Formula: C₁₂H₁₄O₄
• Molecular Weight: 222.24
• Mol File: 7510-46-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 379.8°Cat760mmHg
• Flash Point: 145.6°C
• Appearance: /
• Density: 1.172g/cm³
• Vapor Pressure: 1.91E-06mmHg at 25°C
• CAS DataBase Reference: (2-METHOXY-4-PROPENYL-PHENOXY)-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (2-METHOXY-4-PROPENYL-PHENOXY)-ACETIC ACID(7510-46-5)
• EPA Substance Registry System: (2-METHOXY-4-PROPENYL-PHENOXY)-ACETIC ACID(7510-46-5)

Safety Data

• Hazardous Substances Data: 7510-46-5(Hazardous Substances Data)

Usage

General Description

(2-METHOXY-4-PROPENYL-PHENOXY)-ACETIC ACID, also known as carboxylic acid 2-(2-methoxy-4-propen-1-ylphenoxy)ethyl ester, is a chemical compound that belongs to the group of acetates. It has a molecular formula of C14H16O4 and a molecular weight of 248.27 g/mol. (2-METHOXY-4-PROPENYL-PHENOXY)-ACETIC ACID is often used in the field of organic synthesis and pharmaceutical research, as it has potential applications in the development of new drugs and pharmaceutical products. Additionally, it may also have practical uses in the production of agrochemicals and other industrial processes. Its specific properties and potential biological activities make it a subject of interest for scientists and researchers studying its potential uses and applications.

InChI:InChI=1/C12H14O4/c1-3-4-9-5-6-10(11(7-9)15-2)16-8-12(13)14/h3-7H,8H2,1-2H3,(H,13,14)/p-1/b4-3+

Upstream product

• 6331-61-9 2-methoxy-4-(2-propenyl)phenoxyacetic acid 
• 97-54-1 2-methoxy-4-propenylphenol 
• 79-11-8 chloroacetic acid 
• 97-53-0 4-allylguaiacol 
• 5932-68-3 (E)-2-methoxy-4-(1-propenyl)phenol 
• 632290-89-2 ethyl 2-(2-methoxy-4-(prop-1-enyl)phenoxy)acetate 
• 1395081-54-5 C₁₄H₁₈O₄ 
• 51264-70-1 ethyl 2-(4-formyl-2-methoxyphenoxy)acetate 

Downstream Products

• 1660-19-1 (4-formyl-2-methoxyphenoxy)acetic acid 
• 121-33-5 vanillin 
• 88425-71-2 2'-methoxy-4'-propylphenoxyacetic acid 
• 93799-45-2 [2-Methoxy-4-((E)-propenyl)-phenoxy]-acetic acid 2,5-dioxo-pyrrolidin-1-yl ester 
• 75-07-0 acetaldehyde 
• 102131-52-2 2,2,5,5-Tetramethyl-2,5-dihydro-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-{2-[2-methoxy-4-((E)-propenyl)-phenoxy]-acetylamino}-propyl)-amide 
• 93799-25-8 2,2,5,5-Tetramethyl-2,5-dihydro-1H-pyrrole-3-carboxylic acid (2-{2-[2-methoxy-4-((E)-propenyl)-phenoxy]-acetylamino}-ethyl)-amide 
• 93799-20-3 2,2,5,5-Tetramethyl-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3-{2-[2-methoxy-4-((E)-propenyl)-phenoxy]-acetylamino}-propyl)-amide 
• 102131-53-3 2,2,5,5-Tetramethyl-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3-{2-[2-methoxy-4-((E)-propenyl)-phenoxy]-acetylamino}-2,2-dimethyl-propyl)-amide 
• 1395081-58-9 (S,E)-4-isopropyl-3-(2-(2-methoxy-4-(prop-1-enyl)phenoxy)acetyl)-5,5-diphenyloxazolidin-2-one 
• 1395081-60-3 (S)-3-((2S,3R)-3-(3,4-dimethoxyphenyl)-3-hydroxy-2-(2-methoxy-4-((E)-prop-1-enyl)phenoxy)propanoyl)-4-isopropyl-5,5-diphenyloxazolidin-2-one 
• 1395081-61-4 (S)-3-((2S,3R)-3-hydroxy-2-(2-methoxy-4-((E)-prop-1-enyl)phenoxy)-3-(3,4,5-trimethoxyphenyl)propanoyl)-4-isopropyl-5,5-diphenyloxazolidin-2-one 
• 1395081-63-6 (1R,2R)-1-(3,4-dimethoxyphenyl)-2-(2-methoxy-4-((E)-prop-1-enyl)phenoxy)propane-1,3-diol 
• 1395081-64-7 (1R,2R)-2-(2-methoxy-4-((E)-prop-1-enyl)phenoxy)-1-(3,4,5-trimethoxyphenyl)propane-1,3-diol 

Relevant articles and documents

Novel coupled molecules from active structural motifs of synthetic and natural origin as immunosuppressants

Introduction: Nitric oxide (NO) is an important mediator in the pathogenesis and control of immune system-related disorders and its levels are modulated by inducible NO synthase (iNOS). Oxidative stress is another pathological indication in majority of autoimmune disorders. The present study aims at the development of coupled molecules via selection of pharmacophores for both immunomodulatory and antioxidant activities through iNOS inhibition. Methods: Variedly substituted coumarin moieties are coupled with naturally occurring phenols through an amide linkage and were predicted for activities using computer-based program PASS. The compounds predicted to have dual activities were synthesized. Docking studies were carried out against iNOS (PDB 1R35) and compounds having good docking score were evaluated for immunomodulatory and antioxidant activities. Results: The synthesized compounds were found to be pure and were obtained in good yields. Compounds with maximum docking score (YR1a, YR2e, YR2c and YR4e) were selected for evaluation by in vitro models. Compounds YR2e and YR2c markedly inhibited the reduction of NBT dye and showed maximum percent iNOS inhibition. In DPPH assay, compound YR4e was observed as the most potent antioxidant (EC50 0.33 μM/mL). Based on these studies, compounds YR2e and YR2c were selected for haemagglutination test. Compound YR2e was observed as the most active immunosuppressant with maximal inhibitory ability of iNOS and NBT reduction and lower HAT value of 3.5. Conclusion: Compound YR2e can be utilized as a pharmacological agent in the prevention or treatment of immunomodulatory diseases such as tumors, rheumatoid arthritis, ulcerative colitis, organ transplant and other autoimmune disorders.